Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Vandenberghe

Showing results (61-70 of 185) with videos related to

Pageof 19
Sort By:
Acta Oncologica (Stockholm, Sweden)|May 1, 2019
Role of interim and end of treatment positron emission tomography for response assessment and prediction of relapse in posttransplant lymphoproliferative disorderCiska-Anne Van Keerberghen, Karolien Goffin, Vibeke Vergote, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 26, 2003
[(18)F]FDG PET monitoring of tumour response to chemotherapy: does [(18)F]FDG uptake correlate with the viable tumour cell fraction?Karoline Spaepen, Sigrid Stroobants, Patrick Dupont, et al.
Blood|April 8, 2011
Smad4 binds Hoxa9 in the cytoplasm and protects primitive hematopoietic cells against nuclear activation by Hoxa9 and leukemia transformationRonan Quéré, Göran Karlsson, Falk Hertwig, et al.
Translational Respiratory Medicine|September 30, 2014
Performance of standard procedures in detection of EGFR mutations in daily practice in advanced NSCLC patients selected according to the ESMO guideline: a large Caucasian cohort studyInge Hantson, Christophe Dooms, Eric Verbeken, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2008
Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutationBarbara Dewaele, Bartosz Wasag, Jan Cools, et al.
Leukemia & Lymphoma|September 18, 2008
Positron emission tomography in mantle cell lymphomaLieselot Brepoels, Sigrid Stroobants, Walter De Wever, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 17, 2018
Other immunomodulatory agent-related lymphoproliferative diseases: a single-center series of 72 biopsy-confirmed casesLukas Marcelis, Charlien Berghen, Alexandra De Zutter, et al.
Genes, Chromosomes & Cancer|December 16, 2006
Array CGH analysis in primary gastrointestinal stromal tumors: cytogenetic profile correlates with anatomic site and tumor aggressiveness, irrespective of mutational statusAgnieszka Wozniak, Raf Sciot, Louis Guillou, et al.
Blood|April 29, 2006
Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutantEls Lierman, Cedric Folens, Elizabeth H Stover, et al.
Haematologica|July 8, 2008
t(3;11)(q12;p15)/NUP98-LOC348801 fusion transcript in acute myeloid leukemiaPaolo Gorello, Lucia Brandimarte, Roberta La Starza, et al.
Pageof 19

Showing results (61-70 of 185) with videos related to

Sort By:
Pageof 19
Acta Oncologica (Stockholm, Sweden)|May 1, 2019
Role of interim and end of treatment positron emission tomography for response assessment and prediction of relapse in posttransplant lymphoproliferative disorderCiska-Anne Van Keerberghen, Karolien Goffin, Vibeke Vergote, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 26, 2003
[(18)F]FDG PET monitoring of tumour response to chemotherapy: does [(18)F]FDG uptake correlate with the viable tumour cell fraction?Karoline Spaepen, Sigrid Stroobants, Patrick Dupont, et al.
Blood|April 8, 2011
Smad4 binds Hoxa9 in the cytoplasm and protects primitive hematopoietic cells against nuclear activation by Hoxa9 and leukemia transformationRonan Quéré, Göran Karlsson, Falk Hertwig, et al.
Translational Respiratory Medicine|September 30, 2014
Performance of standard procedures in detection of EGFR mutations in daily practice in advanced NSCLC patients selected according to the ESMO guideline: a large Caucasian cohort studyInge Hantson, Christophe Dooms, Eric Verbeken, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2008
Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutationBarbara Dewaele, Bartosz Wasag, Jan Cools, et al.
Leukemia & Lymphoma|September 18, 2008
Positron emission tomography in mantle cell lymphomaLieselot Brepoels, Sigrid Stroobants, Walter De Wever, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 17, 2018
Other immunomodulatory agent-related lymphoproliferative diseases: a single-center series of 72 biopsy-confirmed casesLukas Marcelis, Charlien Berghen, Alexandra De Zutter, et al.
Genes, Chromosomes & Cancer|December 16, 2006
Array CGH analysis in primary gastrointestinal stromal tumors: cytogenetic profile correlates with anatomic site and tumor aggressiveness, irrespective of mutational statusAgnieszka Wozniak, Raf Sciot, Louis Guillou, et al.
Blood|April 29, 2006
Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutantEls Lierman, Cedric Folens, Elizabeth H Stover, et al.
Haematologica|July 8, 2008
t(3;11)(q12;p15)/NUP98-LOC348801 fusion transcript in acute myeloid leukemiaPaolo Gorello, Lucia Brandimarte, Roberta La Starza, et al.
Pageof 19